Market Place
Sourcing Support
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy
11 Jun 2024 //
PRESS RELEASE
Exothera Launches Nucleic Acids Service Offering Powered by Ntensify
26 Mar 2024 //
PRESS RELEASE
NIH and Exothera partner to produce GMP intranasal vaccine against SARS-CoV-2
24 Aug 2023 //
ONCLIVE
Exothera Nucleic Acids Strengthens Team with Industry Expert
09 May 2023 //
PRESS RELEASE
Remedium, Exothera Partner on Scale-Up, Demonstration Runs for AAV2-FGF18
22 Mar 2023 //
CONTRACT PHARMA
Exothera Names Darren Leva as Chief Business Officer
01 Feb 2023 //
CONTRACT PHARMA
Valo Therapeutics selects Exothera to develop oncolytic Adenovirus manufacturing
11 Jan 2023 //
GLOBENEWSWIRE
Exothera Forms Vaccine Manufacturing Partnership with Vaccizone
07 Jul 2022 //
CONTRACTPHARMA
Exothera announces AAV manufacturing collaboration with LogicBio & Polyplus
15 Jun 2022 //
PRNEWSWIRE
ReiThera and Exothera to Make Vaccines for Low- and Middle-Income Countries
13 Apr 2022 //
CONTRACTPHARMA
Rokote Partners with Exothera to Bring FINCoVac 2.0 to Phase I/II Trials
31 Mar 2022 //
CONTRACTPHARMA
GMP certification for Exothera further extends its viral vector mfg capacity
23 Mar 2022 //
PRNEWSWIRE
IDT Biologika collaborates with Exothera to push the scale-up of viral vaccines
01 Mar 2022 //
PRNEWSWIRE
Exothera Appoints Hanna Lesch as Chief Technology Officer
27 Oct 2021 //
CONTRACTPHARMA
Genequine Selects Exothera to Support Gene Therapy Manufacturing
10 Sep 2021 //
GENENGNEWS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.